Fig. 3From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancerKaplan-Meier curves of the IMVigor 210 study, using the Tumor Microenvironment Metascore (TMM) as a continuous variable split by quartilesBack to article page